temsirolimus (Torisel)

Indications

• renal cell carcinoma

Dosage

• IV infusion over 30-60 minutes weekly

Adverse effects

• allergic reactions, angioedema
• weakness, fatigue
• edema
• headache
• dysgeusia
• sore mouth or throat
• loss of appetite, weight loss
• nausea/vomiting
• constipation, diarrhea, bloody stools
• urinary frequency, dysuria, hematuria, oliguria
• back pain, myalgia, arthralgia
• epistaxis
• changes in fingernails or toenails
• dry skin
• tachycardia
• acne
• insomnia
• depression
• dyspnea, tachypnea
• dysphagia
• flushing
• chest pain
• dizziness, fainting
• new or worsening abdominal pain
• blurred vision
• dysarthria
• confusion
• focal neurologic deficit

Mechanism of action

• protein kinase inhibitor, inhibits mTOR
• leads to cell cycle arrest in G1 phase
• inhibits tumor angiogenesis by reducing synthesis of VEGF

More general terms

• antineoplastic enzyme inhibitor